Pharmacokinetic evaluation and antitumor activity of 2-methoxyestradiol nanosuspension

References

• Akers MJ. (2002). Excipient-drug interactions in parenteral formulations. j Pharm Sci, 91:2283–2300.
   PubMed Web of Science ®Google Scholar
• Ben-Harari RR, Amit T, Youdim MB. (1983). Binding of oestradiol, progesterone and prolactin in rat lung. j Endocrinol, 97:301–310.
   PubMed Web of Science ®Google Scholar
• Bernhard HL, Bohm Muller RH. (1999). Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs. Pharm Sci Tech Today, 2:336–339.
   PubMedGoogle Scholar
• Brannon-Peppas L, Blanchette JO. (2004). Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev, 56:1649–1659.
   PubMed Web of Science ®Google Scholar
• Chandana M, Sanjeeb K S. (2010). The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials, 31:6597–6611.
   PubMed Web of Science ®Google Scholar
• Chavanpatil MD, Patil Y, Panyam J. (2006). Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int j Pharm, 320:150–156.
   PubMed Web of Science ®Google Scholar
• Du B, Li XT, Zhao Y, A YM, Zhang ZZ. (2010). Preparation and characterization of freeze-dried 2-methoxyestradiol nanoparticle powders. Pharmazie, 65:471–476.
   PubMed Web of Science ®Google Scholar
• Du B, Li Y, Li XT, A YM, Zhang ZZ. (2009). LC with fluorescence detection for the tissue pharmacokinetics of 2-methoxyestradiol solution and liposome after intravenous administrations to rats. Chromatographia, 70:1287–1290.
   Web of Science ®Google Scholar
• Floyd AG. (1999). Top ten considerations in the development of parenteral emulsions. Pharm Sci Technol Today, 4:134–143.
   PubMedGoogle Scholar
• Ganta S, Paxton JW, Baguley BC, Garg S. (2009). Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int j Pharm, 367:179–186.
   PubMed Web of Science ®Google Scholar
• Gao S, Fan G, Hong Z, Yin X, Yang S, Wu Y. (2006). HPLC determination of polydatin in rat biological matrices: application to pharmacokinetic studies. j Pharm Biomed Anal, 41:240–245.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L et al. (2008). Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int j Pharm, 355:321–327.
   PubMed Web of Science ®Google Scholar
• Hany SM, Peter Y, Nicholas B. (2009). Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. Int J Pharm, 375:107–113.
   PubMed Web of Science ®Google Scholar
• Hecq J, Deleers M, Fanara D, Vranckx H, Boulanger P, Le Lamer S et al. (2006). Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur j Pharm Biopharm, 64:360–368.
   PubMed Web of Science ®Google Scholar
• Hintz RJ, Johnson KC. (1989). The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm, 51:9–17.
   Web of Science ®Google Scholar
• Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM. (2008). Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev, 34:592–602.
   PubMed Web of Science ®Google Scholar
• James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C et al. (2007). Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs, 25:41–48.
   PubMed Web of Science ®Google Scholar
• Jouyban A. (2007). In silico prediction of drug solubility in water-dioxane mixtures using the Jouyban-Acree model. Pharmazie, 62:46–50.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. (2007). Nanosizing–oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 59:631–644.
   PubMed Web of Science ®Google Scholar
• Kipp JE. (2004). The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int j Pharm, 284:109–122.
   PubMed Web of Science ®Google Scholar
• Kyung DL. (1992). Recognition of liposomes by cells: In vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochimica et Biophys. Acta (BBA)-Biomembranes, 1103:185–197.
   Web of Science ®Google Scholar
• Lawrence MJ, Rees GD. (2000). Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev, 45:89–121.
   PubMed Web of Science ®Google Scholar
• Lipinski CA. (2001). Avoiding investment in doomed drugs. Is poor solubility an industry wide problem? Curr Drug Discov, 1:17–19.
   Google Scholar
• Lipinski CA. (2002). Poor aqueous solubility - an industry wide problem in drug discovery. Am Pharm Rev, 5:82–85.
   Google Scholar
• Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. j Pharm Sci, 85:1017–1025.
   PubMed Web of Science ®Google Scholar
• Lou H, Zhang X, Gao L, Feng F, Wang J, Wei X et al. (2009). In vitro and in vivo antitumor activity of oridonin nanosuspension. Int j Pharm, 379:181–186.
   PubMed Web of Science ®Google Scholar
• Lu B. (2005). New techniques and new dosage forms of drugs, 2nd ed., People’s Medical Publishing House: Bei Jing, 158–167.
   Google Scholar
• Mattheolabakis G, Taoufik E, Haralambous S, Roberts ML, Avgoustakis K. (2009). In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur j Pharm Biopharm, 71:190–195.
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge E, Liversidge GG, Cooper ER. (2003). Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur j Pharm Sci, 18:113–120.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev, 53:283–318.
   PubMed Web of Science ®Google Scholar
• Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. j Immunol Methods, 65:55–63.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Ghosh RN, Maxfield FR. (1997). Endocytosis. Physiol Rev, 77:759–803.
   PubMed Web of Science ®Google Scholar
• Müller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47:3–19.
   PubMed Web of Science ®Google Scholar
• Muller RH, Keck CM. (2004). Challenges and solutions for the delivery of biotech drugs–a review of drug nanocrystal technology and lipid nanoparticles. j Biotechnol, 113:151–170.
   PubMed Web of Science ®Google Scholar
• Müller RH, Keck CM. (2007). Improvement of delivery & solubility of poorly soluble drugs by nanonisation. LTS Academy, Petersberg, p. 12–17.
   Google Scholar
• Müller RH, Peters K, Becker R, Kruss B. (1995). Nanosuspensions for the i.v. administration of poorly soluble drugs-stability during sterilization and long-term storage. 22nd International Symposium of Controlled Release of Bioactive Materials, Washington DC, 574–575.
   Google Scholar
• Müller RH, Peters K. (1998). Nanosuspensions for the formulation of poorly soluble drugs: preparation by a size reduced technique. Int J Pharm, 160:229–237.
   Web of Science ®Google Scholar
• Nakano M. (2000). Places of emulsions in drug delivery. Adv Drug Deliv Rev, 45:1–4.
   PubMed Web of Science ®Google Scholar
• Pace SN, Pace GW, Parikh I., Mishra AK. (1999). Novel injectable formulations of insoluble drugs. Pharm Technol, 23:116–134.
   Google Scholar
• Patravale VB, Date AA, Kulkarni RM. (2004). Nanosuspensions: a promising drug delivery strategy. j Pharm Pharmacol, 56:827–840.
   PubMed Web of Science ®Google Scholar
• Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Müller RH et al. (2000). Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. j Antimicrob Chemother, 45:77–83.
   PubMed Web of Science ®Google Scholar
• Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3:785–796.
   PubMed Web of Science ®Google Scholar
• Radtke M. (2001). NanopureTM pure drug nanoparticles for the formulation of porly soluble drugs. New Drugs, 3:62–68.
   Google Scholar
• Rieux A, des Fievez V, Garinot M, Schneider YJ, Préat V. (2006). Nanoparticles as potential oral delivery systems of proteins and vaccines: amechanistic approach. J Control Release, 116:1–27.
   PubMed Web of Science ®Google Scholar
• Shailendra SR, Prahlad CG. (2008). Effect of surface charge and density of distearylphosphatidylethanolamine-mPEG-2000 (DSPE-mPEG-2000) on the cytotoxicity of liposome-entrapped ricin: Effect of lysosomotropic agents. Int J Pharm, 350:79–94.
   PubMedGoogle Scholar
• Stegemann S, Leveiller F, Franchi D, de Jong H, Lindén H. (2007). When poor solubility becomes an issue: from early stage to proof of concept. Eur j Pharm Sci, 31:249–261.
   PubMed Web of Science ®Google Scholar
• Stella VJ, Rajewski RA. (1997). Cyclodextrins: their future in drug formulation and delivery. Pharm Res, 14:556–567.
   PubMed Web of Science ®Google Scholar
• Stovall DM, Givens C, Keown S, Hoover KR, Barnes R, Harris C, Lozano J, Nguyen M, Rodriguez E, Acree JWE, Abraham MH. (2005). Solubility of crystalline nonelectrolyte solutes in organic solvents: mathematical correlation of 4-chloro-3-nitrobenzoic acid and 2-chloro-5-nitrobenzoic acid solubilities with the abraham solvation parameter model. Phys Chem Liq, 43:351–360.
   Web of Science ®Google Scholar
• Sun W, Mao S, Shi Y, Li LC, Fang L. (2011). Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption. j Pharm Sci, 100:3365–3373.
   PubMed Web of Science ®Google Scholar
• Watts AB, McConville JT, Williams RO. (2008). Current therapies and technological advances in aqueous aerosol drug delivery. Drug Dev Ind Pharm, 34:913–922.
   PubMed Web of Science ®Google Scholar
• Wu L, Tang C, Yin C. (2010). Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol). Drug Dev Ind Pharm, 36:439–448.
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen XG, Sun GZ, Huang L, Cheng XJ. (2010). Effect of molecular weight on the oleoyl-chitosan nanoparticles as carriers for doxorubicin. Colloids Surf b Biointerfaces, 77:125–130.
   PubMed Web of Science ®Google Scholar
• Zhang X, Huang H, Xu Z, Zhan R. (2010). 2-Methoxyestradiol blocks cell-cycle progression at the G2/M phase and induces apoptosis in human acute T lymphoblastic leukemia CEM cells. Acta Biochim Biophys Sin (Shanghai), 42:615–622.
   PubMed Web of Science ®Google Scholar